Loading data for FDMT — first visit, this takes a few seconds.

알림

4D Molecular Therapeutics... (FDMT)

NasdaqGS: FDMT · 실시간 가격 · USD

14.72

+0.18 (1.24%)

종가 기준: Aug 18, 2026, 3:59 PM

1.24% (1D)

매수호가	10.76
시가총액	835.29M
매출 (ttm)	92.01M
순이익 (ttm)	-179.18M
베타	2.69
EPS (ttm)	-2.63
P/E (ttm)	n/a
선행 P/E	-3.7
P/B (ttm)	2.05
P/S (ttm)	9.08
Earnings Date	Nov 10, 2026

매도호가	17.94
거래량	1,602,245
평균 거래량 (20일)	909,940
시가	14.25
전일 종가	14.54
일중 범위	13.91 - 15.04
52주 범위	5.97 - 15.04
애널리스트	n/a
목표주가	n/a
배당	n/a
배당락일	n/a

FDMT 소개

4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company's lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injec...

[더 보기]

산업 Biotechnology

섹터 Healthcare

IPO 일자 Dec 11, 2020

직원 수 196

상장 거래소 NasdaqGS

티커 FDMT

웹사이트 https://www.4dmoleculartherapeutics.com

전체 기업 정보

재무 실적

2025년 4D Molecular Therapeutics의 매출은 85.21M로, 전년 37K 대비 230,194.59% 증가했습니다. 순이익은 -140.11M로, -12.9% 감소했습니다.

재무제표

어닝 서프라이즈

4D Molecular Therapeutics가 Aug 13, 2026에 분기 실적을 발표했습니다:

매출 $3.05M 예상치 하회 $0, 및 21664.29% 전년 대비 성장.

EPS -1.04 예상치 하회 -0.02, 및 -6.12% 전년 대비 감소.

다음 실적 발표

4D Molecular Therapeutics Inc.의 실적 발표 예정일은 Nov 10, 2026, 정규장 중입니다.
애널리스트 예상 매출은 ... 업그레이드

뉴스

1일 전 · Stocktwits

OCUL, FDMT Stock Clock Best Day In Weeks After EyePoint’s Trial Setback — Here’s Why

EyePoint Pharmaceuticals said on Monday that its late-stage trial of DURAVYU, an experimental long-lasting eye implant for wet age-related macular degeneration, missed its main goal.

5일 전 · Zacks

4D Molecular Therapeutics, Inc. (FDMT) Reports Q2 Loss, Tops Revenue Estimates

4D Molecular Therapeutics (FDMT) delivered earnings and revenue surprises of 0.00% and +142.37%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the sto...

6일 전 · Zacks

MediWound (MDWD) Reports Q2 Loss, Beats Revenue Estimates

MediWound (MDWD) delivered earnings and revenue surprises of -1.32% and +19.57%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

1주 전 · Zacks

Collegium Pharmaceutical (COLL) Beats Q2 Earnings and Revenue Estimates

Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of +14.29% and +1.20%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stoc...

2주 전 · Zacks

Bioventus (BVS) Q2 Earnings Meet Estimates

Bioventus (BVS) delivered earnings and revenue surprises of 0.00% and -1.16%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

2 페이지 중 1